297 related articles for article (PubMed ID: 32719672)
1. Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy.
Wu J; Yuan X; Wang B; Gu R; Li W; Xiang X; Tang L; Sun H
Front Microbiol; 2020; 11():1576. PubMed ID: 32719672
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
4. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
5. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
Front Immunol; 2020; 11():1022. PubMed ID: 32574260
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus disease 2019 (COVID-19): current status and future perspectives.
Li H; Liu SM; Yu XH; Tang SL; Tang CK
Int J Antimicrob Agents; 2020 May; 55(5):105951. PubMed ID: 32234466
[TBL] [Abstract][Full Text] [Related]
7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
8. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
Zhou H; Ni WJ; Huang W; Wang Z; Cai M; Sun YC
Front Immunol; 2022; 13():834942. PubMed ID: 35450063
[TBL] [Abstract][Full Text] [Related]
9. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
11. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
12. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
13. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
14. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Alnefaie A; Albogami S
Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
[TBL] [Abstract][Full Text] [Related]
15. Potential pathogenesis of severe acute respiratory syndrome coronavirus 2.
Wu T; Zhang H; Hu E; Ma J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):591-597. PubMed ID: 32879112
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines.
Akbar SMF; Al Mahtab M; Khan S
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992199
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
18. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
19. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
